SlideShare a Scribd company logo
1 of 1
Download to read offline
2nd Annual Market Access Day
            Pricing of Pharmaceuticals:
Is There A Universal Foundation To Set A Fair Price?
      3 December 2010 - Paris, Ecole du Val de Grâce
                        In the context of the current economic crisis and increasing budget constraints for healthcare
                 expenditure, pricing of pharmaceuticals has become an even more sensitive subject than usual. For
                 this reason, for the second annual Market Access Day in Paris, EMAUD gathered experts from North
                 America and Europe who contributed their viewpoints on the concept of fair pricing, answering the
                 question: “Pricing of pharmaceuticals: is there a universal foundation to set a fair price?”
                        Over a hundred healthcare industry professionals attended and the event was an enriching
                 meeting with a high level of interaction and discussion. Representatives from G-BA, NICE, EMA, EFPIA,
                 Andalusia, Catsalut, and INSERM, attended, as well as professors from the universities of Pittsburg,
                 McMaster, Twente, and Tufts. Speakers evaluated the performance of the pricing systems currently in
                 place and explored what could be the answer to setting a ‘fair price’ for pharmaceuticals. Many felt
                 that although all reforms aim at aligning value and price, affordability has become a key element of
                 market access. It is therefore difficult to draw specific lessons applicable to all markets and to supply a
                 single answer to define what fair pricing is; however, many countries are currently trying to integrate
                 objective affordability limits in their pricing practices.                                www.emaud.org

More Related Content

Similar to 2nd Annual Ma Day Feedback Note

Health technology assessment
Health technology assessmentHealth technology assessment
Health technology assessmentpranaliparab
 
Pharma 2020: Marketing the future Which path will you take?
Pharma 2020: Marketing the future Which path will you take?Pharma 2020: Marketing the future Which path will you take?
Pharma 2020: Marketing the future Which path will you take?brandsynapse
 
Personalized Medicine: Uptake Challenges
Personalized Medicine: Uptake ChallengesPersonalized Medicine: Uptake Challenges
Personalized Medicine: Uptake Challengesexecutiveinsight
 
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
2010JanFeb PharmaceuticalMarketingEurope Feature IftheshoefitsAleksandar Ruzicic
 
The Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACThe Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACQuintilesIMS Asia Pacific
 
10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) PpPiyush Patel
 
Making the case for cost-effective wound management
Making the case for cost-effective wound managementMaking the case for cost-effective wound management
Making the case for cost-effective wound managementGNEAUPP.
 
HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Hea...
HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Hea...HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Hea...
HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Hea...Office of Health Economics
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
 
Market access quiz 2020 01-guide
Market access quiz 2020 01-guideMarket access quiz 2020 01-guide
Market access quiz 2020 01-guidepharmaLevers GmbH
 
ORIGINAL ARTICLEThe Health Care Value TransparencyMovement.docx
ORIGINAL ARTICLEThe Health Care Value TransparencyMovement.docxORIGINAL ARTICLEThe Health Care Value TransparencyMovement.docx
ORIGINAL ARTICLEThe Health Care Value TransparencyMovement.docxgerardkortney
 
Challenges to improve medicines transparency in Ghana
Challenges to improve medicines transparency in GhanaChallenges to improve medicines transparency in Ghana
Challenges to improve medicines transparency in GhanaMeTApresents
 
Patient perspective on immune oncology
Patient perspective on immune oncologyPatient perspective on immune oncology
Patient perspective on immune oncologyLungCancerEU
 
Differential pricing of_pharmaceuticals_1561916577
Differential pricing of_pharmaceuticals_1561916577Differential pricing of_pharmaceuticals_1561916577
Differential pricing of_pharmaceuticals_1561916577RamiroCazco2
 
Value based healthcare 2020
Value based healthcare 2020Value based healthcare 2020
Value based healthcare 2020Future Agenda
 
Case study for failure.pdf
Case study for failure.pdfCase study for failure.pdf
Case study for failure.pdfShahena2
 
Accountability in Healthcare: Collaboration and Analytics are Key
Accountability in Healthcare: Collaboration and Analytics are KeyAccountability in Healthcare: Collaboration and Analytics are Key
Accountability in Healthcare: Collaboration and Analytics are KeyBukmarker
 
Multi-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKMulti-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKOffice of Health Economics
 

Similar to 2nd Annual Ma Day Feedback Note (20)

Health technology assessment
Health technology assessmentHealth technology assessment
Health technology assessment
 
Pharma 2020: Marketing the future Which path will you take?
Pharma 2020: Marketing the future Which path will you take?Pharma 2020: Marketing the future Which path will you take?
Pharma 2020: Marketing the future Which path will you take?
 
Personalized Medicine: Uptake Challenges
Personalized Medicine: Uptake ChallengesPersonalized Medicine: Uptake Challenges
Personalized Medicine: Uptake Challenges
 
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
2010JanFeb PharmaceuticalMarketingEurope Feature Iftheshoefits
 
The Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACThe Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APAC
 
WP_oncology_molecule_value_d01
WP_oncology_molecule_value_d01WP_oncology_molecule_value_d01
WP_oncology_molecule_value_d01
 
10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp
 
Making the case for cost-effective wound management
Making the case for cost-effective wound managementMaking the case for cost-effective wound management
Making the case for cost-effective wound management
 
HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Hea...
HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Hea...HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Hea...
HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Hea...
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharma
 
Market access quiz 2020 01-guide
Market access quiz 2020 01-guideMarket access quiz 2020 01-guide
Market access quiz 2020 01-guide
 
ORIGINAL ARTICLEThe Health Care Value TransparencyMovement.docx
ORIGINAL ARTICLEThe Health Care Value TransparencyMovement.docxORIGINAL ARTICLEThe Health Care Value TransparencyMovement.docx
ORIGINAL ARTICLEThe Health Care Value TransparencyMovement.docx
 
Challenges to improve medicines transparency in Ghana
Challenges to improve medicines transparency in GhanaChallenges to improve medicines transparency in Ghana
Challenges to improve medicines transparency in Ghana
 
Patient perspective on immune oncology
Patient perspective on immune oncologyPatient perspective on immune oncology
Patient perspective on immune oncology
 
Differential pricing of_pharmaceuticals_1561916577
Differential pricing of_pharmaceuticals_1561916577Differential pricing of_pharmaceuticals_1561916577
Differential pricing of_pharmaceuticals_1561916577
 
Value based healthcare 2020
Value based healthcare 2020Value based healthcare 2020
Value based healthcare 2020
 
Case study for failure.pdf
Case study for failure.pdfCase study for failure.pdf
Case study for failure.pdf
 
Accountability in Healthcare: Collaboration and Analytics are Key
Accountability in Healthcare: Collaboration and Analytics are KeyAccountability in Healthcare: Collaboration and Analytics are Key
Accountability in Healthcare: Collaboration and Analytics are Key
 
Payer agreements
Payer agreementsPayer agreements
Payer agreements
 
Multi-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKMulti-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UK
 

2nd Annual Ma Day Feedback Note

  • 1. 2nd Annual Market Access Day Pricing of Pharmaceuticals: Is There A Universal Foundation To Set A Fair Price? 3 December 2010 - Paris, Ecole du Val de Grâce In the context of the current economic crisis and increasing budget constraints for healthcare expenditure, pricing of pharmaceuticals has become an even more sensitive subject than usual. For this reason, for the second annual Market Access Day in Paris, EMAUD gathered experts from North America and Europe who contributed their viewpoints on the concept of fair pricing, answering the question: “Pricing of pharmaceuticals: is there a universal foundation to set a fair price?” Over a hundred healthcare industry professionals attended and the event was an enriching meeting with a high level of interaction and discussion. Representatives from G-BA, NICE, EMA, EFPIA, Andalusia, Catsalut, and INSERM, attended, as well as professors from the universities of Pittsburg, McMaster, Twente, and Tufts. Speakers evaluated the performance of the pricing systems currently in place and explored what could be the answer to setting a ‘fair price’ for pharmaceuticals. Many felt that although all reforms aim at aligning value and price, affordability has become a key element of market access. It is therefore difficult to draw specific lessons applicable to all markets and to supply a single answer to define what fair pricing is; however, many countries are currently trying to integrate objective affordability limits in their pricing practices. www.emaud.org